PubMed Wilding JPH, Batterham RL, Calanna S, et al
Weight regulation is controlled by complex biological systems
The FDA has ceased compounded tirzepatide following the stabilization of the national supply of GLP-1 medications, which includes tirzepatide
So far, the trials seem to show: high reduction in weight, hovering around 28% for those on a 12-milligram dose self-reported improvements in cardiometabolic risk factors like high blood pressure, insulin, and fasting glucose promising results for type 2 diabetes and fatty liver disease a reduction in pain from knee osteoarthritis Retatrutide may be valuable for those who have had limited success with other weight loss drugs, have a higher BMI, or are at significant metabolic risk
Surgery or other procedures that use anesthesia or deep sedationMay increase risk of pulmonary aspiration (food or liquid getting into the lungs) during surgery or other procedures